Search results
Results from the WOW.Com Content Network
On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn ...
By Ludwig Burger (Reuters) -Sanofi stock plunged on Friday, wiping 20 billion euros ($21 billion) off its market value, after it abandoned its 2025 profit target under a plan to list its consumer ...
In October 2023, Sanofi SA (NASDAQ:SNY) announced its plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment ...
Novavax stock skyrocketed on Friday, nearly doubling on the news French drug and vaccine giant Sanofi would invest $1.2 billion in a deal for Novavax's COVID-19 vaccine and take a minority stake ...
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
(Reuters) -Sanofi vaunted 12 drugs in development with the potential to make more than $1 billion in annual sales, but failed to reverse a recent plunge in its stock when it gave up a 2025 profit ...
Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi. It was the second largest French pharmaceutical company [6] before it was acquired by Hoechst AG of Frankfurt, Germany in 1997, with pharmaceutical operations combined into the Hoechst Marion Roussel (HMR) division in the United States.
Although the latest news from the laboratory was mixed for pharmaceutical company Sanofi (NASDAQ: SNY) on Tuesday, investors gave the company the benefit of the doubt. They bid the share price up ...